Alzheimer's Disease Biomarkers Study

At what estimated number of years before diagnosis did the CSF biomarker concentrations in the Alzheimer's disease group diverge from those in the cognitively normal group for amyloid-beta (Aβ)42?

Which CSF biomarker showed divergence between the Alzheimer's disease group and the cognitively normal group approximately 10 years before diagnosis?

What type of assessments were conducted at 2-year-to-3-year intervals on a subgroup of participants in the study?

When did the changes in CSF biomarker levels in the Alzheimer's disease group initially accelerate?

How many participants who developed Alzheimer's disease were matched with participants who had normal cognition in the study?

At what estimated number of years before diagnosis did hippocampal volume begin to show divergence between the two groups?

What was the estimated number of years before diagnosis when neurofilament light chain levels started to show divergence between the Alzheimer's disease group and the cognitively normal group?

At what estimated number of years before diagnosis did the ratio of amyloid-beta (Aβ)42 to Aβ40 begin to show divergence between the two groups?

When did the cognitive decline in the Alzheimer's disease group start to accelerate according to the study findings?

At what estimated number of years before diagnosis did phosphorylated tau 181 levels diverge between the Alzheimer's disease group and the cognitively normal group?

What was the median follow-up duration in the study as reported in the text?

After how many years before diagnosis did total tau levels in the Alzheimer's disease group show divergence from those in the cognitively normal group?